Seres Therapeutics, Inc. (MCRB)
MCRB Stock Price Chart
Explore Seres Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze MCRB price movements and trends.
MCRB Company Profile
Discover essential business fundamentals and corporate details for Seres Therapeutics, Inc. (MCRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jun 2015
Employees
103.00
CEO
Eric D. Shaff
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB Financial Timeline
Browse a chronological timeline of Seres Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is $0.05.
Earnings released on 6 Aug 2025
EPS came in at -$2.27 surpassing the estimated -$2.72 by +16.54%.
Earnings released on 7 May 2025
EPS came in at -$2.24 falling short of the estimated -$0.67 by -234.33%.
Stock split effective on 22 Apr 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2025
EPS came in at -$0.32 falling short of the estimated -$0.17 by -88.24%.
Earnings released on 13 Nov 2024
EPS came in at -$6.60 falling short of the estimated -$5.00 by -32.00%.
Earnings released on 13 Aug 2024
EPS came in at -$4.40 surpassing the estimated -$5.60 by +21.43%.
Earnings released on 8 May 2024
EPS came in at -$5.40 surpassing the estimated -$7.20 by +25.00%.
Earnings released on 5 Mar 2024
EPS came in at -$6.40 surpassing the estimated -$8.00 by +20.00%, while revenue for the quarter reached $64.00K , missing expectations by -81.71%.
Earnings released on 2 Nov 2023
EPS came in at -$7.40 surpassing the estimated -$9.40 by +21.28%, while revenue for the quarter reached $310.00K , missing expectations by -11.43%.
Earnings released on 8 Aug 2023
EPS came in at $7.20 falling short of the estimated $11.00 by -34.55%, while revenue for the quarter reached $126.47M , beating expectations by +0.61%.
Earnings released on 9 May 2023
EPS came in at -$11.40 matching the estimated -$11.40, while revenue for the quarter reached -$522.00K , missing expectations by -137.83%.
Earnings released on 7 Mar 2023
EPS came in at -$10.80 falling short of the estimated -$8.20 by -31.71%, while revenue for the quarter reached $975.00K , missing expectations by -83.75%.
Earnings released on 2 Nov 2022
EPS came in at -$9.80 falling short of the estimated -$9.00 by -8.89%, while revenue for the quarter reached $3.44M , missing expectations by -50.83%.
Earnings released on 3 Aug 2022
EPS came in at -$14.00 falling short of the estimated -$11.60 by -20.69%, while revenue for the quarter reached $1.22M , missing expectations by -73.23%.
Earnings released on 4 May 2022
EPS came in at -$12.20 falling short of the estimated -$11.20 by -8.93%, while revenue for the quarter reached $1.49M , missing expectations by -82.41%.
Earnings released on 1 Mar 2022
EPS came in at -$11.00 falling short of the estimated -$9.00 by -22.22%, while revenue for the quarter reached $7.22M , missing expectations by -41.07%.
Earnings released on 10 Nov 2021
EPS came in at $14.40 surpassing the estimated -$9.40 by +253.19%, while revenue for the quarter reached $126.73M , missing expectations by -68.54%.
Earnings released on 3 Aug 2021
EPS came in at -$10.60 falling short of the estimated -$8.20 by -29.27%, while revenue for the quarter reached $5.26M , missing expectations by -2.36%.
Earnings released on 4 May 2021
EPS came in at -$7.80 falling short of the estimated -$6.60 by -18.18%, while revenue for the quarter reached $5.72M , beating expectations by +34.78%.
Earnings released on 2 Mar 2021
EPS came in at -$3.60 surpassing the estimated -$5.20 by +30.77%, while revenue for the quarter reached $17.56M .
Earnings released on 9 Nov 2020
EPS came in at -$7.20 falling short of the estimated -$4.80 by -50.00%, while revenue for the quarter reached $1.42M , beating expectations by +8.23%.
MCRB Stock Performance
Access detailed MCRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.